Navigation path

Additional tools

    Profile of registrant

Grünenthal GmbH

Identification number in the register: 67826544528-01
Registration date: 14/11/2010 18:46:49

The information on this entity was last modified on: 20/10/2014 09:16:41
The date of the last annual update was: 20/10/2014 09:16:41

This entry follows the format of the previous Register. It will be changed to the new format when the entity makes the next update.
Next update due latest on: 27/04/2015

    Registrant : Organisation or self-employed individual

Grünenthal GmbH


Gesellschaft mit beschränkter Haftung

    Section of registration

II - In-house lobbyists and trade/professional associations

Companies & groups

    Contact details

Zieglerstraße, 6
Aachen D-52099

(+49) 241 569 0

(+49) 241 569 3474

    Person with legal responsibility

Mr  Eric-Paul Pâques

Chairman of the Corporate Executive Board

    Person in charge of EU relations

Mr  Konrad Labuschagne

Governmental Affairs and Health Policy

    Goals / remit

The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain treatment, its objective is to become the most patient-centric company in the field of pain and thus to be a leader in therapy innovation.

Grünenthal is one of the last five remaining research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. Research and development costs amounted to about 27 percent of revenues in 2013. Grünenthal's research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. We are intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies.

Altogether, the Grünenthal Group has affiliates in 25 countries worldwide. Grünenthal products are sold in more than 155 countries and approx. 5,500 employees are working for the Grünenthal Group worldwide. In 2013, Grünenthal achieved revenues of €901 mn.

More information:



Grünenthal supports the multistakeholder platform "Sociatal Impact of Pain" (SIP, Furthermore Grünenthal activities in Brussels deal with issues related to healthcare, pain care, pharmaceuticals, innovation and research and intellectual property.

    Number of persons involved in the activities described in the box above


    Persons accredited for access to European Parliament premises

First name Surname Start Date End Date
Konrad Labuschagne 21/05/2014 19/05/2015

    Fields of interest

  • Competition
  • Customs
  • Economic and Financial Affairs
  • Employment and Social Affairs
  • Enlargement
  • Enterprise
  • General and Institutional Affairs
  • Humanitarian Aid
  • Internal Market
  • Public Health
  • Regional Policy
  • Research and Technology
  • Taxation
  • Trans-European Networks

    Membership and affiliation

Grünenthal is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA)

    Financial data

01/2013  -  01/2014

< 50,000  €

0 €

0 €

    Code of conduct

By its registration the organisation has signed the Transparency Register Code of Conduct.